News from regado biosciences, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 20, 2015, 07:00 ET REMINDER: Regado Biosciences and Tobira Therapeutics Merger Agreement Conference Call Set for 8:30 a.m. EST Today, Jan. 20

 Regado Biosciences, Inc. (NASDAQ: RGDO) and Tobira Therapeutics, Inc. will conduct a call at 8:30 a.m. EST today, Jan. 20, to discuss the...


Jan 14, 2015, 08:00 ET Regado Biosciences and Tobira Therapeutics Announce Merger Agreement to Create Leading NASH Company

Regado Biosciences, Inc. (NASDAQ: RGDO) and Tobira Therapeutics, Inc. today announced that they have entered into a definitive agreement under...


Nov 05, 2014, 16:30 ET Regado Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update

 Regado Biosciences, Inc. (Nasdaq: RGDO), today announced its third quarter 2014 financial results. A conference call and webcast to discuss...


Oct 30, 2014, 07:30 ET Regado Biosciences to Provide Third Quarter 2014 Financial Results

 Regado Biosciences, Inc. (Nasdaq: RGDO), today announced that it will hold a conference call and live audio webcast on Thursday, November 6,...


Oct 10, 2014, 07:30 ET Regado Biosciences Appoints Michael A. Metzger CEO

 Regado Biosciences, Inc. (NASDAQ: RGDO), today announced the appointment of Michael A. Metzger, president of Regado, to the additional post of...


Sep 24, 2014, 16:53 ET Regado Biosciences Announces Workforce Reduction and Provides Update on Strategic Direction

Regado Biosciences, Inc. (NASDAQ: RGDO), today announced a reduction of its workforce of approximately 60%, or 20 employees, across all operational...


Aug 25, 2014, 06:30 ET Regado Biosciences Permanently Halts REGULATE-PCI Clinical Trial

 Regado Biosciences, Inc.  today announced the permanent termination of enrollment in its REGULATE-PCI phase 3 trial for its lead program,...


Aug 11, 2014, 16:30 ET Regado Biosciences Announces Second Quarter 2014 Financial Results and Corporate Highlights

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit...


Jul 29, 2014, 16:10 ET Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit...


Jul 09, 2014, 16:05 ET Regado Biosciences Announces Clinical Hold of REGULATE-PCI Trial Following Voluntary Halt of Trial by Regado

Regado Biosciences, Inc., (NASDAQ: RGDO) today announced that, further to their decision to voluntarily pause enrollment in their REGULATE-PCI...


Jul 02, 2014, 18:13 ET Regado Announces Initiation Of DSMB Review Of REGULATE-PCI Data

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit...


Jun 23, 2014, 07:30 ET Regado Biosciences' REG2 Demonstrates Dose and Concentration-Dependent Suppression of Thrombin Generation

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the discovery and development of actively controllable aptamer...


Jun 18, 2014, 07:30 ET Regado Biosciences Appoints Pharmaceutical Business Leader Drew Fromkin to Board of Directors

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit (also...


May 29, 2014, 07:30 ET Regado Biosciences to Present at the Jefferies 2014 Global Healthcare Conference

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit...


May 19, 2014, 07:30 ET Regado Biosciences Appoints Nicholas Pelliccione, Ph.D., Senior Vice President of Regulatory Affairs and Quality Assurance and Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit...


May 14, 2014, 07:30 ET Regado Biosciences Announces First Quarter 2014 Financial Results and Corporate Highlights

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of the...


May 09, 2014, 07:30 ET Regado Biosciences Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively...


May 07, 2014, 07:30 ET Regado Biosciences to Provide First Quarter 2014 Financial Results and Corporate Highlights

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...


May 01, 2014, 07:30 ET Regado Biosciences Appoints R. Don Elsey Chief Financial Officer

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively...


Apr 16, 2014, 09:35 ET Regado Biosciences Announces Closing of Public Offering of Common Stock

 Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the closing of its previously announced underwritten public offering. The gross...


Apr 11, 2014, 07:30 ET Regado Biosciences Announces Pricing of Public Offering of Common Stock

 Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the pricing of its previously announced underwritten public offering of 10,000,000...


Apr 02, 2014, 21:20 ET Regado Achieves 1,000-Patient Milestone in Phase 3 Trial of REG1

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company leading the development of actively controllable therapeutics for acute care...


Mar 20, 2014, 07:30 ET Regado Biosciences to Present at the 21st Annual Future Leaders in the Biotech Industry Conference

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its...


Mar 12, 2014, 17:35 ET Regado Biosciences Announces Year-End 2013 Financial Results and Corporate Highlights

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its...


Mar 10, 2014, 07:30 ET FDA Designates Regado's REG1 in PCI as a Fast Track Development Program

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of actively controllable therapeutics, today...